() () CEO Ahmad Doroudian tells Proactive its encouraged by positive results from a clinical trial by a UK biotech, which suggested that an interferon inhalation treatment for coronavirus reduces the need for intensive care.
Doroudian says data from the () trial showed that people who received SNG001, an inhaled formulation of interferon beta, had a 79% lower risk of developing severe coronavirus disease compared to those given the placebo.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE
